Short answer
Corcept Therapeutics Inc (CORT) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). President of Corcept Endocrinology Sean Maduck resigns effective October 1, 2026.
Corcept Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- President of Corcept Endocrinology Sean Maduck resigns effective October 1, 2026
- No disagreement cited with operations, financial statements, policies or practices
- Consulting agreement runs through September 30, 2027, unless terminated earlier
- Monthly consulting fee of $57,000, with 30 days’ termination notice
- Outstanding stock options continue vesting during the consulting term
Item 7.01 · Regulation FD Disclosure
- CEO transition announced: Justin Gunn succeeds retiring Mr. Maduck
- Leadership change creates execution and strategy continuity considerations
- Exhibit 99.1 contains the company’s detailed transition announcement
Item EX-99.1 · Exhibit EX-99.1
- Sean Maduck retiring as Endocrinology president after 14 years, remaining as senior commercial advisor
- Justin Gunn assumes Endocrinology leadership October 1 and joins Executive Team, reporting to CEO Joseph Belanoff
- Leadership change places commercial executive with oncology launch experience over Cushing’s syndrome business
- Transition comes as Corcept targets broader awareness and treatment reach in Cushing’s syndrome
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corcept Therapeutics Inc 8-K filings
Get the next CORT 8-K as it lands
Follow CORT for push alerts, or ask the research agent what this filing means.